PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : A

Records returned : 177 (on 17 May 2024 at 08:26:46).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Abacavir
No Information Returned
01.01.01
05.03.01
Abacavir and lamivudine
TEST
Amber
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
01.01.01
05.03.01
Abacavir/lamivudine/zidovudine
TEST
Amber
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
10.01.03
Abatacept
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only. NON-FORMULARY for moderate disease
Abciximab
No Information Returned
Abemaciclib
No Information Returned
Abiraterone
No Information Returned
Acamprosate calcium
No Information Returned
Acarbose
No Information Returned
Acebutolol hydrochloride
No Information Returned
Acebutolol hydrochloride with diuretic
No Information Returned
10.01.01
Aceclofenac
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Acemetacin
No Information Returned
Acenocoumarol
No Information Returned
Acetarsol
No Information Returned
Acetazolamide
No Information Returned
Acetazolamide sodium
No Information Returned
Acetic acid
No Information Returned
Acetohydroxamic acid
No Information Returned
Acetylcholine chloride
No Information Returned
03.07.00
11.08.01
07.04.04
Acetylcysteine
Reduction of sputum viscosity
Green (see narrative)
Formulations :
  • Effervescent tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe generically as 600mg effervescent tablets sugar free. Do not use in patients with bronchospasm or history of asthma. Do not use in fluid or sodium restricted patients.
03.07.00
11.08.01
07.04.04
Acetylcysteine
Dry eyes
Red
Formulations :
  • Eye drops (preservative free)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
5% and 10% preservative free (unlicensed) eye drops reserved for specialist use in severe dry eye
03.07.00
11.08.01
07.04.04
Acetylcysteine
Reduction of sputum viscosity
Non Formulary
Formulations :
  • Capsules
  • Granules
  • Oral solution
  • Powder
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
U
Important
These are either unlicensed or are not considered cost-effective treatment options - see guidelines for recommended products.
Acetyl-l-carnitine
No Information Returned
Aciclovir
No Information Returned
Aciclovir sodium
No Information Returned
Acipimox
No Information Returned
Acitretin
No Information Returned
Aclidinium bromide
No Information Returned
Aclidinium bromide/formoterol
No Information Returned
03.04.01
Acrivastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
10.01.03
Adalimumab
Behcet's syndrome
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Highly specialist centres only.
10.01.03
Adalimumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Adalimumab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
10.01.03
Adalimumab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Prescribe by brand
10.01.03
Adalimumab
Non-radiographic axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Adalimumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
10.01.03
Adalimumab
Psoriasis
See Below
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Adapalene
No Information Returned
Adapalene and benzoyl peroxide
No Information Returned
Addaven (Generic)
No Information Returned
Adefovir dipivoxil
No Information Returned
Ademetionine
No Information Returned
Adenosine
No Information Returned
03.04.03
11.06.00
Adrenaline
Anaphylaxis
Green
Formulations :
  • Auto-injector
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand. Injection technique is device-specific
Afatinib
No Information Returned
Agalsidase alfa
No Information Returned
Agalsidase beta
No Information Returned
Agomelatine
No Information Returned
Albendazole
No Information Returned
Albiglutide
No Information Returned
Albumin solution
No Information Returned
Alclometasone dipropionate
No Information Returned
Alcohol
No Information Returned
Aldesleukin
No Information Returned
Alectinib
No Information Returned
08.02.03
10.01.03
Alemtuzumab
Behcet's syndrome
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Highly specialised centres only
Alendronic acid
No Information Returned
Alendronic acid/colecalciferol
No Information Returned
Alexitol sodium
No Information Returned
Alfacalcidol
No Information Returned
04.07.02
15.01.04
Alfentanil hydrochloride
Pain
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
See separate listings for palliative care and use in anaesthesia.
07.04.01
Alfuzosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
Alginic acid compound preparations
No Information Returned
Alglucosidase alfa
No Information Returned
03.04.01
Alimemazine tartrate
Sleep disorders in children and adolescents
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Un
Alirocumab
No Information Returned
Aliskiren
No Information Returned
Alitretinoin
No Information Returned
Alkyl sulfate
No Information Returned
Alkyl sulphate
No Information Returned
10.01.04
Allopurinol
Hyperuricaemia and Gout
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.07.04
Almotriptan
Migraine (acute)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Not 1st line. Generic sumatriptan, naratriptan, rizatripan, zolmitriptan are preferred.
Alogliptin
No Information Returned
Alogliptin/metformin
No Information Returned
Alprazolam
No Information Returned
07.04.05
Alprostadil
Erectile dysfunction
Green (see narrative)
Formulations :
  • Cream
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Treatments for ED on the NHS require an SLS endorsement.
Only in patients who do not respond to PDE-5 inhibitors.
07.04.05
Alprostadil
Erectile dysfunction
Blue
Formulations :
  • Intracavernosal injection
  • Intraurethral
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Treatments for ED on the NHS require an SLS endorsement.
Alteplase
No Information Returned
Aluminium acetate
No Information Returned
Aluminium and magnesium and activated simeticone
No Information Returned
Aluminium and magnesium and oxetacaine
No Information Returned
Aluminium chloride
No Information Returned
Aluminium hydroxide
No Information Returned
Aluminium oxide
No Information Returned
Aluminium sulfate
No Information Returned
Alverine citrate
No Information Returned
Alverine citrate compound preparations
No Information Returned
Alverine citrate/simeticone
No Information Returned
04.09.01
05.03.04
Amantadine hydrochloride
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Ambrisentan
No Information Returned
Amifostine
No Information Returned
Amikacin
No Information Returned
Amiloride hydrochloride
No Information Returned
Amiloride hydrochloride with loop diuretics
No Information Returned
Amiloride hydrochloride with thiazides
No Information Returned
Aminoglutethimide
No Information Returned
Aminophylline
No Information Returned
Aminophylline hydrate
No Information Returned
Aminosalicylic acid
No Information Returned
Amiodarone hydrochloride
No Information Returned
Amisulpride
No Information Returned
04.03.01
04.07.03
04.07.04
Amitriptyline hydrochloride
Migraine (prevention)
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.03.01
04.07.03
04.07.04
Amitriptyline hydrochloride
Pain (Neuropathic)
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Preferred
Amlodipine
No Information Returned
Ammonium acetate
No Information Returned
Ammonium bicarbonate
No Information Returned
Ammonium chloride
No Information Returned
Ammonium chloride/diphenhydramine hydrochloride
No Information Returned
Amobarbital
No Information Returned
Amobarbital sodium
No Information Returned
Amorolfine hydrochloride
No Information Returned
Amoxapine
No Information Returned
Amoxicillin
No Information Returned
Amoxicillin sodium
No Information Returned
Amphoteracin
No Information Returned
Amphotericin
No Information Returned
Ampicillin
No Information Returned
Amprenavir
No Information Returned
Amsacrine
No Information Returned
Amyl nitrite
No Information Returned
Amylmetacresol
No Information Returned
Anagrelide hydrochloride
No Information Returned
10.01.03
Anakinra
Inflammatory conditions (excluding IBD)
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
Anakinra
Any paediatric use
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
BlueTeq
Analgesics with anti-emetics
No Information Returned
Anastrozole
No Information Returned
Androstanalone
No Information Returned
Anidulafungin
No Information Returned
Antazoline
No Information Returned
Antazoline hydrochloride
No Information Returned
11.04.02
Antazoline with xylometazoline
Allergic conjunctivitis
Green
Formulations :
  • Eye drops
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Sodium cromoglycate 2% or Antazoline with Xylometazoline (Otrivine-Antistin) are the preferred antihistamine/anti-inflammatory eye drops
Anthrax vaccine
No Information Returned
Anti-D (Rh-) immunoglobulin
No Information Returned
Antithrombin alfa
No Information Returned
Antithymocyte immunoglobulin
No Information Returned
01.07.02
Anusol-HC
Haemorrhoids
Green
Formulations :
  • Ointment
  • Suppositories
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Apalutamide
No Information Returned
02.08.02
Apixaban
Atrial fibrillation
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Preferred
04.09.01
Apomorphine hydrochloride
Parkinson's disease
Amber
Formulations :
  • Pre-filled syringe
  • Subcutaneous injection (sc)
  • Subcutaneous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Apomorphine hydrochloride
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Apomorphine hydrochloride hemihydrate
No Information Returned
Apraclonidine
No Information Returned
10.01.03
Apremilast
Psoriatic arthritis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Apremilast
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
10.01.03
Apremilast
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Aprepitant
No Information Returned
Aprotinin
No Information Returned
Arachis oil
No Information Returned
Argipressin
No Information Returned
Aripiprazole
No Information Returned
Arnica montana
No Information Returned
Arsenic
No Information Returned
Artemether with lumefantrine
No Information Returned
Artificial saliva
No Information Returned
Ascorbic acid
No Information Returned
Ascorbic acid (Eye)
No Information Returned
Asenapine
No Information Returned
Asfotase alfa
No Information Returned
Asparaginase
No Information Returned
Aspirin
No Information Returned
Aspirin and caffeine
No Information Returned
Aspirin and papaveretum
No Information Returned
Aspirin and paracetamol
No Information Returned
Aspirin combined preparations
No Information Returned
Atazanavir
No Information Returned
Atazanavir and cobicistat
No Information Returned
Atenolol
No Information Returned
Atenolol with calcium channel blocker
No Information Returned
Atenolol with diuretic
No Information Returned
Atenolol with thiazides
No Information Returned
04.04.00
Atomoxetine hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Atorvastatin
No Information Returned
07.01.03
Atosiban
Delay of premature labour
Red
Formulations :
  • Infusion
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Under specialist supervision in hospital
Atovaquone
No Information Returned
Atracurium besilate
No Information Returned
Atropine sulfate
No Information Returned
Auranofin
No Information Returned
07.04.01
07.04.05
Avanafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
07.04.01
07.04.05
Avanafil
Erectile dysfunction
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
07.04.01
07.04.05
Avanafil
Erectile dysfunction combination therapy
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Avelumab
No Information Returned
07.04.05
Aviptadil with phentolamine mesilate
Erectile dysfunction
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Axitinib
No Information Returned
Azacitidine
No Information Returned
Azapropazone
No Information Returned
Azatadine maleate
No Information Returned
08.02.01
Azathioprine
Gastroenterology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
08.02.01
Azathioprine
Hepatology Indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
08.02.01
Azathioprine
Haematology Indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
08.02.01
Azathioprine
Dermatology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
08.02.01
Azathioprine
Rheumatology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Uveitis
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Scleritis
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Respiratory disease indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Renal indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Oral disease indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Neurology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
08.02.01
Azathioprine
Transplantation
N/A
Formulations :
  • Suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Azelaic acid
No Information Returned
Azelastine hydrochloride
No Information Returned
Azilsartan medoxomil
No Information Returned
Azithromycin
No Information Returned
Aztreonam
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More